AACE Communities MENA Conference
Event start date: 11/11/2022
Credit claim deadline: 12/31/2022
Statement of Need
AACE Communities MENA Conference is designed to provide a forum for medical professionals to enhance their patient-centered approaches, to help optimize and personalize their patient outcomes by immersing themselves in the most relevant clinical approaches and technology advances.
This program targets all medical professionals that care for patients with endocrine disorders including endocrinologists, cardiologists, nephrologists, primary care physicians, advanced providers, nurses, diabetes educators, and pharmacists. The program is also intended for health care professionals at any stage in their career.
By the end of the meeting, participants will be able to:
- Discuss the latest clinical practice guidelines on endocrine disorders, including diabetes mellitus, diabetes technology, obesity, pituitary and adrenal disorders, thyroid cancer and bone metabolism.
- Summarize key characteristics of evidence-based assessment and management options for patients with endocrine disorders and endocrine neoplasia.
- Apply multidisciplinary approaches on the management and treatment options for patients with endocrine disorders for improved patient outcomes.
- Formulate management plans that include optimal team-based, patient centered care of patients with endocrine disorders.
Accreditation and Designation Statements
The American College of Endocrinology (ACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Endocrinology (ACE) designates this live activity for a maximum of 14.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure and Conflicts of Interest Policy
The American Association of Clinical Endocrinologists (AACE) remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of AACE to eliminate all situations of potential conflict of interest, but rather to enable those who are working with AACE to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the CME Subcommittee to ensure that such situations are properly evaluated and, if necessary, resolved. AACE educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all AACE accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities.
|Planner Name||Ineligible Company||Relevant Financial Relationship|
|Susan Samson, MD, PhD, FACE||Chiasma/Amryt|
|Jaime Almandoz, MD||Novo Nordisk |
|Vinaya Simha, MD||Pfizer||Consultant|
|Sarah Nadeem, MD, FACE||Novo Nordisk||Consultant|
|Nasreen Alfaris, MD||Novo Nordisk||Speakers Bureau, Consultant|
All of the relevant financial relationships listed for these individuals have been mitigated. All other planners for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
|Faculty Name||Ineligible Company||Relevant Financial Relationship|
|Zahid Ahmad, MD||Akcea, Regeneron||Consultant|
|Diane Donegan, MD||Corcept, Acendis, Amyrt |
|Research Funding |
|Barton Duell, MD||Regeneron, Regenxbio, Retrophin (Travere) |
Akcea, Amryt, Novartis, Kaneka, Regeneron
|Research Funding |
|W. Timothy Garvey, MD||Novo Nordisk, Epitomee, Pfizer, and Eli Lilly |
Eli Lilly, Novo Nordisk, Pfizer, JAZZ Pharmaceuticals, Boehringer-Ingelheim, Fractyl, and Alnylam
|Principal investigator - no direct payments received |
|Kristien Boelaert, MD||Lilly||Consultant|
|Adriana Ioachimescu, MD||Amryt (former Chiasma), Xeris (former Strongbridge) and Recordati Rare Diseases |
Amryt (former Chiasma), Xeris (former Strongbridge), HRA Pharma and Recordati Rare Diseases
|Research Funding |
|Mohamed Hassanein ,MD||Novo, Lilly, Sanofi, Novartis, BI, MSD, Servier and Abbott |
Nova, Sanofi, Lilly, BI
|Speaker Bureau |
|Aisha Sheikh, MD||NovoNordisk, Lily, Sanofi Aventis, Martin Dow, and Horizon||Speaker Honoraria|
|Khalid Al Waili, MD||Sanofi, Abbott, and Novartis||Speaker Bureau|
|Ashish Chintakuntlawar, MD||Eisai, Genmab, AstraZeneca, PDS biotech, Rakuten Medical |
HRA pharma, Rakuten Medical
|Research Funding - Institutional |
Consultant - Institutional
|Amir Babiker, MD||Novo Nordisk |
|Speaker Bureau |
All of the relevant financial relationships listed for these individuals have been mitigated. All other faculty for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
None of the reviewers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.